Astellas strengthens gene therapy portfolio with Iveric Bio acquisition
CREDIT: GOOGLE
Astellas Pharma has acquired Iveric Bio, a US-based biotech firm, for $5.9 billion.
CREDIT: GOOGLE
Astellas strengthens gene therapy portfolio with Iveric Bio acquisition
The deal is expected to bolster Astellas' portfolio in ophthalmology and gene therapy.
CREDIT: GOOGLE
Iveric Bio's Zimura could become a blockbuster drug
Iveric Bio's lead drug candidate, Zimura, is a treatment for a degenerative eye disease known as geographic atrophy.
CREDIT: GOOGLE
Astellas expands presence in US market with Iveric Bio purchase
Zimura has shown promising results in clinical trials and could become a blockbuster drug with potential annual sales of over $1 billion.
CREDIT: GOOGLE
Astellas to acquire Iveric Bio to boost ophthalmology portfolio
The acquisition is part of Astellas' strategy to expand its presence in the US market.
CREDIT: GOOGLE
Iveric Bio to become Astellas' wholly-owned subsidiary
The transaction is expected to close by the end of 2021, subject to regulatory approval and other customary closing conditions.
CREDIT: GOOGLE
Astellas' largest-ever purchase of a biotech firm Iveric Bio
Iveric Bio will become a wholly-owned subsidiary of Astellas following the acquisition.
CREDIT: GOOGLE
Astellas financing Iveric Bio acquisition with cash and bank borrowings
The acquisition represents Astellas' largest-ever purchase of a biotech firm.
CREDIT: GOOGLE
Astellas to acquire Iveric Bio pending regulatory approval
Astellas will finance the acquisition using cash on hand and borrowings from banks.
CREDIT: GOOGLE
Astellas aims to grow through Iveric Bio acquisition
The acquisition is expected to be accretive to Astellas' earnings in the medium term.
CREDIT: GOOGLE
Iveric Bio's Zimura shows promising results in clinical trials
Learn more